Dendreon announced that Jason O’Neill will join the company as CEO, as of the beginning of June. O’Neill brings with him experience of working at the largest pharma companies in the industry, including Bristol Myers Squibb, Sanofi, and Roche.
O’Neill’s most recent role in the industry was CEO of Iridium Therapeutics, which he held for two years until the end of 2018.
Dendreon called to attention O’Neill’s experience in managing Sanofi’s oncology portfolio for six years as part of the reason for bringing him into the leadership position at Dendreon.
The company’s lead product is Provenge (sipuleucel-T), which is an immunotherapy for the treatment of advanced prostate cancer.
O’Neill, CEO of Dendreon, said of his appointment: “My experience developing successful growth and market entry strategies is a timely addition to the company as we work to build a robust R&D pipeline and expand access to the life-extending benefits of Provenge in the US and internationally.”
Broadening access to the product into the international markets was another reason given for his appointment, with his time working in Asia-Pacific market cited as a benefit for expanding the company into a ‘multi-product, multi-market company’.